Live
Lupin, the Indian drugmaker had agreed to buy a portfolio of 21 drugs from Japan’s Shionogi & Co for 15.4 billion yen (USD 150 million).
The companies said in a statement that the portfolio will be transferred to Lupin on December 31, subject to regulatory approvals and certain closing conditions.
The acquisition that is going to be done by Lupin’s Japanese generic drug unit Kyowa Pharmaceutical Industry Co Ltd, will be providing Lupin the access to Japanese branded pharmaceutical market and strengthen its speciality business portfolio.
